Suzhou Zelgen Biopharmaceuticals Co Ltd Total Assets
Suzhou Zelgen Biopharmaceuticals Co Ltd total assets. Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) holds total assets worth CN¥3.01 Billion CNY (≈ $440.95 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Suzhou Zelgen Biopharmaceuticals Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
Total assets of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024. This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data. See 688266 live share price for real-time trading data and today's change.
Suzhou Zelgen Biopharmaceuticals Co Ltd - Asset Composition Analysis
Suzhou Zelgen Biopharmaceuticals Co Ltd Total Assets Breakdown (December 2024)
Suzhou Zelgen Biopharmaceuticals Co Ltd total assets breakdown as of December 2024. Suzhou Zelgen Biopharmaceuticals Co Ltd's total assets of CN¥3.01 Billion consist of 85.7% current assets and 14.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 71.7% |
| Accounts Receivable | CN¥153.01 Million | 5.1% |
| Inventory | CN¥182.86 Million | 6.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥50.01 Million | 1.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Suzhou Zelgen Biopharmaceuticals Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Suzhou Zelgen Biopharmaceuticals Co Ltd's current assets represent 85.7% of total assets in 2024, an increase from 59.0% in 2016.
- Cash Position: Cash and equivalents constituted 71.7% of total assets in 2024, up from 12.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 9.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 6.1% of total assets.
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Suzhou Zelgen Biopharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 1.95 | 11.85 |
| Quick Ratio | 1.72 | 1.83 | 11.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.15 Billion | CN¥1.25 Billion | CN¥1.53 Billion |
Suzhou Zelgen Biopharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Suzhou Zelgen Biopharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.75 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | 4.1% |
| Total Assets | CN¥3.00 Billion |
| Market Capitalization | $3.52 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Suzhou Zelgen Biopharmaceuticals Co Ltd's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Suzhou Zelgen Biopharmaceuticals Co Ltd's assets grew by 4.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual total assets of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.00 Billion ≈ $439.67 Million |
+4.07% |
| 2023-12-31 | CN¥2.89 Billion ≈ $422.49 Million |
+73.06% |
| 2022-12-31 | CN¥1.67 Billion ≈ $244.13 Million |
-4.45% |
| 2021-12-31 | CN¥1.75 Billion ≈ $255.49 Million |
-11.39% |
| 2020-12-31 | CN¥1.97 Billion ≈ $288.31 Million |
+515.20% |
| 2019-12-31 | CN¥320.27 Million ≈ $46.87 Million |
-29.59% |
| 2018-12-31 | CN¥454.88 Million ≈ $66.56 Million |
+208.12% |
| 2017-12-31 | CN¥147.63 Million ≈ $21.60 Million |
+7.60% |
| 2016-12-31 | CN¥137.20 Million ≈ $20.08 Million |
-- |
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more